ArticlePloS one2017
Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04244383 (Expression of Inflammasomes in HCV Patients Before and After Treatment), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Expression of Inflammasomes in HCV Patients Before and After Treatment
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- The inflammasome next door: characterizing pyroptosis induction in HCV-infected and uninfected bystander cellsFrontiers in cellular and infection microbiology · 2025Article
- Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals.Microorganisms · 2024Review
- Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.BMC infectious diseases · 2024Article
- Chronic viral infection compromises the quality of circulating mucosal-invariant T cells and follicular T helper cells via expression of both activating and inhibitory receptors.Research square · 2023Article
- Enhanced TLR3 responsiveness in hepatitis C virus resistant women from the Irish anti-D cohort.Cell reports. Medicine · 2022Article
- Promiscuous Inflammasomes: The False Dichotomy of RNA/DNA Virus-Induced Inflammasome Activation and Pyroptosis.Viruses · 2022Review
- Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CanHepC), the Canadian Association of Hepatology Nurses (CAHN), and the Canadian NASH Network 2022 Abstracts.Canadian liver journal · 2022Article
- Crosstalk Between Pyroptosis and Apoptosis in Hepatitis C Virus-induced Cell Death.Frontiers in immunology · 2022Article
- Single-cell transcriptomic analyses of T cells in chronic HCV-infected patients dominated by DAA-induced interferon signaling changes.PLoS pathogens · 2021Article
- Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure.Pathogens (Basel, Switzerland) · 2021Review
- Difference of Intrahost Dynamics of the Second Human Pegivirus and Hepatitis C Virus in HPgV-2/HCV-Coinfected Patients.Frontiers in cellular and infection microbiology · 2021Article
- Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.The Journal of clinical investigation · 2020Article
- Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.Scientific reports · 2020Article
- Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges.International journal of medical sciences · 2020Review
- Review
- Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence.Cells · 2019Review
- Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation.PLoS pathogens · 2019Article
- Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.Gastroenterology · 2019Review
- Revisiting the Paradox of Interferon-Stimulated Gene Expression as a Predictor of Hepatitis C Virus Treatment Response, a Decade Later.Hepatology (Baltimore, Md.) · 2018Article
- Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C.Mediators of inflammation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
resultsFirst, in patients receiving two different combinations of DAAs, we found that DAAs induced not only rapid viral clearance, but also a re-setting of antiviral immune responses in the peripheral blood. Specifically, we see a rapid decline in the expression of genes associated with chronic IFN stimulation (IFIT3, USP18, IFIT1) as well as a rapid decline in genes associated with inflammation (IL1β, CXCL10, CXCL11) in the peripheral blood that precedes the complete removal of virus from the blood. Interestingly, this rapid reversal of innate immune activation was not seen in patients who successfully clear chronic HCV infection using IFN-based therapy. Next, using a novel humanized mouse model (Fah-/-RAG2-/-IL2rgnull-FRG), we assessed the changes that occur in the hepatic tissue following DAA treatment. DAA-mediated rapid HCV clearance resulted in blunting of the expression of proinflammatory responses while functionally restoring the RIG-I/MAVS axis in the liver of humanized mice.
conclusionsCollectively, our data demonstrate that the rapid viral clearance following treatment with DAAs results in the rebalancing of innate antiviral response in both the peripheral blood and the liver as well as enhanced antiviral signaling within previously infected hepatocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.